• Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG 

  Izquierdo Delgado, E (2020-07-31)

  Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ...
• Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. 

  van Erp, AEM; van Houdt, L; Hillebrandt-Roeffen, MHS; van Bree, NFHN; Flucke, UE; Mentzel, T; Shipley, J; Desar, IME; Fleuren, EDG; Versleijen-Jonkers, YMH; van der Graaf, WTA

  <h4>Purpose</h4>Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase ...
• Immunomodulatory activity of IR700-labelled affibody targeting HER2. 

  Mączyńska, J; Da Pieve, C; Burley, TA; Raes, F; Shah, A; Saczko, J; Harrington, KJ; Kramer-Marek, G (2020-10-20)

  There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing ...
• Hypoxia and its therapeutic possibilities in paediatric cancers. 

  Bernauer, C; Man, YKS; Chisholm, JC; Lepicard, EY; Robinson, SP; Shipley, JM (2020-10-27)

  In tumours, hypoxia-a condition in which the demand for oxygen is higher than its availability-is well known to be associated with reduced sensitivity to radiotherapy and chemotherapy, and with immunosuppression. The ...
• Mesothelin-targeted CAR-T cell therapy for solid tumors. 

  Klampatsa, A; Dimou, V; Albelda, SM (2020-11-12)

  <b>Introduction</b>: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has ...
• ¹⁸F-meta-fluorobenzylguanidine (¹⁸F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models. 

  Turnock, S; Turton, DR; Martins, CD; Chesler, L; Wilson, TC; Gouverneur, V; Smith, G; Kramer-Marek, G (2020-12)

  Targeted radiotherapy with ¹³¹I-mIBG, a substrate of the human norepinephrine transporter (NET-1), shows promising responses in heavily pre-treated neuroblastoma (NB) patients. Combinatorial approaches that ...
• Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. 

  Pawlyn, C; Cairns, D; Menzies, T; Jones, J; Jenner, M; Cook, G; Boyd, K; Drayson, M; Kaiser, M; Owen, R; Gregory, W; Morgan, G; Jackson, G; Davies, F (2020-12-03)

  Autologous stem cell transplant (ASCT) remains standard of care for consolidation after induction therapy for eligible newly diagnosed myeloma patients. In recent clinical trials comparing ASCT to delayed ASCT, patients ...
• Targeting p300/CBP axis in lethal prostate cancer. 

  Welti, J; Sharp, A; Brooks, N; Yuan, W; McNair, C; Chand, SN; Pal, A; Figueiredo, I; Riisnaes, R; Gurel, B; Rekowski, J; Bogdan, D; West, W; Young, B; Raja, M; Prosser, A; Lane, J; Thomson, S; Worthington, J; Onions, S; Shannon, J; Paoletta, S; Brown, R; Smyth, D; Harbottle, GW; Gil, VS; Miranda, S; Crespo, M; Ferreira, A; Pereira, R; Tunariu, N; Carreira, S; Neeb, AJ; Ning, J; Swain, A; Taddei, D; International Dream Team, SUTC-P; Schiewer, MJ; Knudsen, KE; Pegg, N; de Bono, JS (2021-01-11)

  Resistance to androgen receptor (AR) blockade in castration resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of the AR (AR-SV). Inhibitors of transcriptional ...
• Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. 

  Jackson, GH; Pawlyn, C; Cairns, DA; de Tute, RM; Hockaday, A; Collett, C; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Rocci, A; Snowden, JA; Jenner, MW; Cook, G; Russell, NH; Drayson, MT; Gregory, WM; Kaiser, MF; Owen, RG; Davies, FE; Morgan, GJ; UK NCRI Haemato-oncology Clinical Studies Group (2021-01-11)

  <h4>Background</h4>Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome ...
• ddPCR-based detection of circulating tumour DNA from paediatric high grade and diffuse midline glioma patients 

  Jones, C
• The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion. 

  Burford, A; Mackay, A; Popov, S; Vinci, M; Carvalho, D; Clarke, M; Izquierdo, E; Avery, A; Jacques, TS; Ingram, WJ; Moore, AS; Frawley, K; Hassall, TE; Robertson, T; Jones, C (2018-01-18)

  Astroblastomas are rare brain tumours which predominate in children and young adults, and have a controversial claim as a distinct entity, with no established WHO grade. Reports suggest a better outcome than high grade ...
• Integration of Multiple Platforms for the Analysis of Multifluorescent Marking Technology Applied to Pediatric GBM and DIPG. 

  Pericoli, G; Petrini, S; Giorda, E; Ferretti, R; Ajmone-Cat, MA; Court, W; Conti, LA; De Simone, R; Bencivenga, P; Palma, A; Di Giannatale, A; Jones, C; Carai, A; Mastronuzzi, A; de Billy, E; Locatelli, F; Vinci, M (2020-09-15)

  The intratumor heterogeneity represents one of the most difficult challenges for the development of effective therapies to treat pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG). These brain tumors ...
• Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition. 

  Nguyen, A; Moussallieh, FM; Mackay, A; Cicek, AE; Coca, A; Chenard, MP; Weingertner, N; Lhermitte, B; Letouzé, E; Guérin, E; Pencreach, E; Jannier, S; Guenot, D; Namer, IJ; Jones, C; Entz-Werlé, N (2017-09)

  Pediatric high grade glioma (pHGGs), including sus-tentorial and diffuse intrinsic pontine gliomas, are known to have a very dismal prognosis. For instance, even an increased knowledge on molecular biology driving this ...
• Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. 

  Haque, F; Varlet, P; Puntonet, J; Storer, L; Bountali, A; Rahman, R; Grill, J; Carcaboso, AM; Jones, C; Layfield, R; Grundy, RG (2017-06-06)

  Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a ...
• Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma. 

  Simpson, AD; Soo, YWJ; Rieunier, G; Aleksic, T; Ansorge, O; Jones, C; Macaulay, VM (2020-03)

  High-grade glioma (HGG) is highly resistant to therapy, prompting us to investigate the contribution of insulin-like growth factor receptor (IGF-1R), linked with radioresistance in other cancers. IGF-1R immunohistochemistry ...
• The long non-coding RNA <i>HOTAIR</i> is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. 

  Xavier-Magalhães, A; Gonçalves, CS; Fogli, A; Lourenço, T; Pojo, M; Pereira, B; Rocha, M; Lopes, MC; Crespo, I; Rebelo, O; Tão, H; Lima, J; Moreira, R; Pinto, AA; Jones, C; Reis, RM; Costello, JF; Arnaud, P; Sousa, N; Costa, BM (2018-03)

  The lncRNA <i>HOTAIR</i> has been implicated in several human cancers. Here, we evaluated the molecular alterations and upstream regulatory mechanisms of <i>HOTAIR</i> in glioma, the most common primary brain tumors, and ...
• Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody 

  Tanaka, T; Thomas, J; Van Montfort, R; Miller, A; Rabbitts, T (Springer Science and Business Media LLC, 2021-12)

  <jats:title>Abstract</jats:title><jats:p>Intracellular antibodies are valuable tools for target validation studies for clinical situations such as cancer. Recently we have shown that antibodies can be used for drug discovery ...
• Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. 

  Collins, DC; Sundar, R; Constantidinou, A; Dolling, D; Yap, TA; Popat, S; O'Brien, ME; Banerji, U; de Bono, JS; Lopez, JS; Tunariu, N; Minchom, A (2020-12-09)

  <h4>Background</h4>Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of the pleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are ...
• Bioluminescence Resonance Energy Transfer 2 (BRET2)-Based RAS Biosensors to Characterize RAS Inhibitors. 

  Bery, N; Rabbitts, TH (2019-06)

  Protein-protein interactions (PPIs) are principle biological processes that control normal cell growth, differentiation, and homeostasis but are also crucial in diseases such as malignancy, neuropathy, and infection. Despite ...
• Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. 

  Rasche, L; Angtuaco, E; McDonald, JE; Buros, A; Stein, C; Pawlyn, C; Thanendrarajan, S; Schinke, C; Samant, R; Yaccoby, S; Walker, BA; Epstein, J; Zangari, M; van Rhee, F; Meissner, T; Goldschmidt, H; Hemminki, K; Houlston, R; Barlogie, B; Davies, FE; Morgan, GJ; Weinhold, N (2017-07)

  ¹⁸F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the ...

View more